Bloomberg Ratings Analysts Reach Consensus Recommendation of “Hold” for Enfusion,
January 30, 2023
Trending News 🌥️
Enfusion ($NYSE:ENFN), Inc. is a publicly-traded financial technology firm that provides a suite of integrated technology solutions to the wealth management and asset management industries. The Bloomberg Ratings research analysts have recently reached a consensus recommendation of “Hold” for Enfusion, Inc., which is the opinion of all six analysts who follow the company. The consensus recommendation of “Hold” is based on the company’s current fundamentals, including its financials, management team, and competitive position in the industry. The analysts believe that while the company’s financials are strong and its management team has proven to be competent, Enfusion, Inc. is facing increasing competition from other financial technology firms. The analysts also note that Enfusion, Inc. has been expanding its operations globally and investing in new technologies, which could lead to potential growth opportunities.
However, the analysts caution that there are still risks to consider when investing in Enfusion, Inc., such as the potential for regulatory changes or market volatility. Overall, the analysts believe that the current stock price is fair and that investors should take a wait-and-see approach when considering Enfusion, Inc. shares. They suggest that investors should monitor the company’s performance, financials, and competitive positioning over time in order to make an informed decision about whether or not to purchase or sell the stock.
Market Price
On Wednesday, the stock of Enfusion, Inc. opened at $12.0 and closed at $11.9, down by 1.8% from the previous closing price of 12.1. The consensus recommendation is based on a combination of factors, including the company’s financial performance and its market position. Analysts are concerned that the company’s revenue and earnings have been declining in recent quarters, suggesting that it may be facing some challenges in its operations.
Additionally, the company’s market share has been declining, which could indicate that it is not competing as effectively as it could be. The consensus recommendation is also based on the company’s current valuation. Since Enfusion, Inc. is trading at a discount to its peers in the industry, it suggests that the market believes the company is overvalued relative to its peers. This could be due to a number of factors, including its current financial performance and its market position. Overall, Bloomberg Ratings Analysts have reached a consensus recommendation of “Hold” for Enfusion, Inc., citing a combination of factors including its declining financial performance and market share, along with its current valuation relative to its peers. Investors should consider these factors before making any decisions regarding this stock. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Enfusion. More…
| Total Revenues | Net Income | Net Margin |
| 141.69 | -208.49 | -125.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Enfusion. More…
| Operations | Investing | Financing |
| 0.82 | -7.83 | 62.47 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Enfusion. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 115.6 | 12.43 | 0.91 |
Key Ratios Snapshot
Some of the financial key ratios for Enfusion are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -216.7% |
| FCF Margin | ROE | ROA |
| -4.9% | -319.2% | -166.0% |
VI Analysis
VI App’s analysis of Enfusion’s fundamentals reveals that it is a medium risk investment from both financial and business perspectives. This means that while there is an opportunity for potential returns, there is also a possibility of losses. The evaluation is based on the company’s financial statements, such as its income statement, balance sheet and cash flow statement, and its business performance. Although the company’s overall risk rating is medium, VI App has detected one risk warning in its financial journal. Signing up with the app will allow you to access more information regarding the warning and to determine whether or not to pursue investing in Enfusion. Enfusion’s fundamentals are a key indicator of its long-term potential, and understanding them is an important step in making an informed decision as to whether or not to invest. By using VI App, investors can accurately assess the company’s financial and business performance and determine if it is a suitable investment opportunity. More…
VI Peers
In the business world, there is always competition. Enfusion Inc is no exception. Its competitors, Redcastle Resources Ltd, WaveDancer Inc, FalconStor Software Inc, are all vying for the same market share. Enfusion Inc has the advantage of being a well-established company with a strong brand. Its competitors are relative newcomers and are still trying to establish themselves in the market. Enfusion Inc is also a market leader in its field, with a strong reputation for quality products and services. Its competitors are still trying to catch up.
– Redcastle Resources Ltd ($ASX:RC1)
Redcastle Resources Ltd is a Canadian mineral exploration company with a focus on gold and copper projects in North America. The company has a market capitalization of 4.92 million as of 2022 and a return on equity of -15.38%. The company’s primary project is the Redcastle Gold Project, located in British Columbia, Canada.
– WaveDancer Inc ($NASDAQ:WAVD)
WaveDancer Inc is a publicly traded company with a market capitalization of 17.49 million as of 2022. The company has a return on equity of -28.79%. WaveDancer Inc is a company that provides wave energy conversion technology and services.
– FalconStor Software Inc ($OTCPK:FALC)
FalconStor Software, Inc. is a software company, which provides data protection and storage management solutions. It offers various solutions for storage virtualization, storage replication, disaster recovery, continuous data protection, and cloud storage. The company was founded by ReiJane Huai and James J. Donovan in October 2000 and is headquartered in Austin, TX.
Summary
Enfusion, Inc. is currently receiving a consensus rating of ‘Hold’ from Bloomberg Ratings Analysts. This suggests that investors should remain neutral on the stock and its potential for future growth. A ‘Hold’ rating typically indicates that the company is performing in line with the market and that there may not be any potential for significant gains. Investors should do their own research before making a decision on investing in Enfusion, Inc. They should consider factors such as the company’s financials, competitive landscape, and management team when deciding whether Enfusion, Inc. is a suitable investment.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
